c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model.

Yin YeXiaojun YangFeifei LiWei LiuWenqing ZhangZhibin Huang

Published in: Animal models and experimental medicine (2022)

In summary, this study suggests that c-myb acts downstream of BCR/ABL1 and is involved in CML progression and is therefore a risk factor and a valuable target for the treatment of CML progression. The model used in the study could be helpful in high-throughput drug screening in CML transformation.

Keyphrases

chronic myeloid leukemia
high throughput
transcription factor
tyrosine kinase
risk factors
acute lymphoblastic leukemia
emergency department
single cell
drug induced